

LANTana: RECRUITING

Patients with neuroendocrine tumours (NETs)

Assessing feasibility of **ASTX727** to re-express **SSR2** in those with **negative/low uptake [68Ga]Ga-DOTA-TATE-PET/CT** who would be otherwise ineligible for protein radionucleotide receptor therapy

Key Eligibility

- Histologic diagnosis of NET (Ki67 <55%)
- No or low uptake on [68Ga]Ga-DOTA-TATE-PET/CT
- ≥1 prior therapy

**Part A Interim Analysis
of 13 Patients
Complete**

Positive Safety Outcome

No discontinuations due to toxicity
Well tolerated

Positive Efficacy Outcome

6 patients showed re-expression following ASTX727

Contact

Patient Referrals

Chief Investigator: Rohini.Sharma2@nhs.net

Senior Research Nurse: Caroline.Ward1@nhs.net

T: 02075942807

A: Hammersmith Hospital
Imperial College Healthcare NHS Trust
London, W12 0HS

Trial Queries - Sponsor

Clinical Trials Manager: c.wyard23@imperial.ac.uk

CHART – Cancer & Haematology Academic Research Team

T: 02033131362

EudraCT: 2020-003800-15
clinicaltrials.gov - NCT05178693

Thank you to our current Referrers:
Dr Dan Krell, *Royal Free Hospital*
Prof. Martyn Caplin, *Royal Free Hospital*

IMPERIAL

All Referrers will be offered authorship in the **publication**

Limited slots left